Close

Forward Pharma (FWP) Bullish Stance Reiterated at Jefferies Following Initial Interference Documents Apr 20, 2015 09:03AM
Patent Interference a 'Binary Event' for Forward Pharma (FWP) But Next Update 13 Months Away, Jefferies Says Apr 15, 2015 08:25AM
Acadia Pharmaceuticals (ACAD) PT Trimmed to $47 at Jefferies; 'Buy' Maintained Mar 12, 2015 07:29AM
Jefferies Says Cost-Effectiveness Analysis Suggests Broad Seattle Genetics (SGEN) Adcetris First-Line Use Feb 9, 2015 07:01AM
Jefferies Sees Upside to Stemline Therapeutics (STML) SL-401 Timeline Jan 30, 2015 08:56AM
View Older Stories

Jan 28, 2015 06:48AM Acadia Pharmaceuticals (ACAD) PT Raised to $50 at Jefferies on Higher Nuplazid Sales Estimates
Jan 20, 2015 07:54AM Neurocrine Bio. (NBIX) PT Raised to $39 at Jefferies
Jan 9, 2015 08:23AM Neurocrine Bio. (NBIX) PT Raised to $32 at Jefferies
Dec 23, 2014 07:55AM Jefferies Says Too Early to Judge the Impact of AbbVi Competition on Gilead (GILD)
Dec 12, 2014 09:14AM Dynavax (DVAX) Bullish Stance Reiterated at Jefferies Following R&D Day
Dec 9, 2014 06:49AM Jefferies Starts Neuroderm Ltd (NDRM) at Buy, $17 PT
Dec 2, 2014 12:46PM Avanir (AVNR) Should Have Gotten at Least $26/Share in Takeover - Jefferies
Nov 10, 2014 06:45AM Jefferies Starts Forward Pharma (FWP) at Buy
Oct 21, 2014 07:55AM Competitor's IDO Partnership Bodes Well for Incyte (INCY), Jefferies Says
Sep 17, 2014 07:47AM Completion of REDUCE-IT Best Way to Maximize Amarin (AMRN) Vascepa L-T Value, Jefferies Says
Sep 17, 2014 07:39AM Auxilium (AUXL) Could Be Worth Up to $45/Share in a Potential Takeover - Jefferies
Sep 10, 2014 07:10AM Auxilium Pharmaceuticals (AUXL) PT, Estimates Raised at Jefferies on Headcount Reduction
Aug 13, 2014 06:52AM Arrowhead Research (ARWR) Bullish Stance Reiterated at Jefferies as ARC-520 Shows Highly Encouraging Efficacy
Aug 4, 2014 07:23AM Jefferies Maintains Bullish Stance on Arena Pharma (ARNA) Despite Weaker Belviq Sales
Aug 4, 2014 06:31AM Jefferies Starts La Jolla Pharma (LJPC) at Buy, Sees 166% Upside
Jul 28, 2014 07:07AM Jefferies Starts Minerva Neurosciences (NERV) at Buy
Jun 12, 2014 07:13AM Auxilium Pharmaceuticals (AUXL) Bullish Stance Reiterated at Jefferies Amid Authorized Generic Testim
May 19, 2014 08:15AM Stemline Therapeutics (STML) PT Cut at Jefferies, Still Sees 288% Upside
May 13, 2014 06:56AM Buy Incyte (INCY) Ahead of ASCO Abstract Release - Jefferies
May 2, 2014 11:50AM Seattle Genetics (SGEN) 'Buy' Reiterated at Jefferies After Q1 Results and Ahead of Pipeline News
May 1, 2014 08:03AM Neurocrine Bio. (NBIX) PT Trimmed at Jeffereis, 'Buy' Maintained
Apr 10, 2014 07:16AM Revlimid Markman Briefing Documents Appear To Favor Celgene (CELG), Jefferies Says
Apr 1, 2014 07:00AM Amarin (AMRN) Price Target Lifted at Jefferies on Kowa Deal
Mar 21, 2014 08:17AM Incyte (INCY) Bullish Thesis Reiterated at Jefferies Post Physician Panel
Mar 19, 2014 06:33AM Jefferies Starts Compugen (CGEN) at Buy
Mar 11, 2014 07:55AM Dynavax (DVAX) 'Buy' Maintained at Jefferies Post Q4
Feb 27, 2014 06:59AM Auxilium Pharmaceuticals (AUXL) Numbers Lifted at Jefferies Ahead of Q4 Earnings Print
Feb 26, 2014 08:30AM Avanir (AVNR) Has Limited Upside Despite Likely Patent Trail Win, Jefferies Says
Feb 24, 2014 06:50AM Jefferies Starts Dicerna Pharmaceuticals (DRNA) at Buy
Feb 7, 2014 07:19AM Arrowhead Research (ARWR) Target Price Doubled at Jefferies
Jan 30, 2014 01:56PM Biogen (BIIB) Target Price Lifted to $358 at Jefferies
Jan 10, 2014 07:12AM Incyte (INCY) Target Price Lifted to $75 at Jefferies on IDO
Dec 18, 2013 06:41AM Jefferies Starts Arrowhead Research (ARWR) at Buy
Dec 18, 2013 06:39AM Jefferies Starts Mirati Therapeutics (MRTX) at Buy
Dec 9, 2013 08:37AM Auxilium Pharmaceuticals (AUXL) PT Lifted to $30 at Jefferies on FDA Approval
Dec 4, 2013 07:55AM OncoMed (OMED) Target Lifted to $46 at Jefferies after Celgene Deal
Nov 11, 2013 08:36AM Arena Pharma (ARNA) Bullish Thesis Intact - Jefferies
Oct 29, 2013 12:16PM Biogen (BIIB) PT Raised to $300 at Jefferies Post Q3
Oct 28, 2013 08:22AM Jefferies Still Positive on Synta (SNTA) Despite Less Robust Data
Oct 25, 2013 11:25AM Celgene (CELG) PT, Estimates Raised at Jefferies on 'Robust' Q3
Oct 17, 2013 06:51AM Amarin (AMRN) PT Slashed to $4 at Jefferies
Oct 15, 2013 03:14PM Amarin (AMRN) FDA Panel Predicted 7-to-3 in Favor of Approval - Jefferies
Oct 14, 2013 01:20PM Net Positive on Amarin (AMRN) Into FDA Panel Vote - Jefferies
Oct 11, 2013 07:48AM Biogen (BIIB) PT Raised at Jefferies Following National Hemophilia Foundation Meeting
Sep 10, 2013 07:12AM Neurocrine Biosciences (NBIX) 'Buy' Rating Intact at Jefferies Despite Setback
Sep 9, 2013 08:58AM Positive Feedback on Immunogen's (IMGN) IMGN-901 - Jefferies
Sep 9, 2013 08:48AM Synta Pharma's (SNTA) Sees Encouraging Physician Feedback On Ganetespib - Jefferies
Sep 9, 2013 08:29AM Rigel Pharma (RIGL) Plans to Shift Fostamatinib Focus From RA to ITP an 'Incremental Positive' - Jefferies
Aug 29, 2013 06:58AM Jefferies Starts Stemline Therapeutics (STML) at Buy, Sees 77% Upside
Aug 14, 2013 07:24AM CaPre to Have Minimal Impact on Amarin (AMRN) Vascepa Sales - Jefferies
View Older Stories